多拉韦林用于HIV合并肥胖患者48周随机对照试验
Do IT研究(ACTG A5391)是一项48周、三平行组、开放标签、多中心随机对照试验,纳入147例接受整合酶抑制剂+TAF/FTC且合并肥胖的HIV感染者,评估换用多拉韦林(DOR)联合TAF/FTC或TDF/FTC对体重的影响。48周时各组体重变化无临床意义的差异,DOR组与继续INSTI组间体重变化差异也无统计学意义。
要点
- 换用DOR+TAF/FTC或DOR+TDF/FTC未产生有临床意义的体重变化。
- DOR与INSTI组间48周体重变化差异无统计学意义。
- 性别、种族及代谢指标未见治疗差异。
核心结论
- 在HIV合并肥胖患者中,从INSTI+TAF/FTC换用DOR/FTC联合TAF或TDF,48周内未产生有临床意义的体重或代谢健康差异。
研究设计与样本
- 48周三平行组开放标签多中心随机对照试验(NCT04636437),147例随机,145例开始治疗。
- 纳入接受INSTI(比克替拉韦、多替拉韦或拉替拉韦)联合TAF/FTC且合并肥胖的HIV感染者。
- 比较换用DOR+TAF/FTC、DOR+TDF/FTC与继续INSTI+TAF/FTC的体重变化。
主要发现
- 48周估计平均体重变化:DOR+TAF/FTC组-0.47%(95%CI:-2.09,1.14),DOR+TDF/FTC组-2.73%(95%CI:-4.22,-1.23),INSTI+TAF/FTC组-1.84%(95%CI:-3.37,-0.30)。
- DOR与INSTI(均联合TAF/FTC)48周体重变化估计平均差异为1.36个百分点(97.5%CI:-1.20,3.92)。
- DOR+TDF/FTC与INSTI+TAF/FTC的体重变化估计平均差异为-0.89个百分点(97.5%CI:-3.34,1.57)。
- 未发现性别或种族间的变异,空腹血脂、胰岛素抵抗、脂肪量或骨密度变化无治疗差异。
临床怎么用
- 对于接受INSTI+TAF/FTC且合并肥胖的HIV感染者,换用DOR联合TAF/FTC或TDF/FTC不是以减重为目的的有效策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Integrase inhibitors (INSTI) and tenofovir alafenamide (TAF) have been associated with greater weight gain compared to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and tenofovir disoproxil fumarate (TDF), but the effects of an antiretroviral regimen switch on weight are unclear. METHODS: This 48-week, 3-parallel group, open-label, multicenter, randomized controlled trial (NCT04636437) in people with HIV and obesity on an INSTI (bictegravir, dolutegravir, or raltegravir) with TAF/emtricitabine (FTC) assessed whether switching to the NNRTI doravirine (DOR) with TAF/FTC or TDF/FTC results in weight loss or stabilization. Treatment effects were estimated using linear regression adjusted for sex, race, and entry weight. RESULTS: Of the 147 participants randomized, 145 initiated their assigned treatment. At entry, median age was 49 years; body mass index was 34.9 kg/m2, and time on INSTI + TAF/FTC was 3.4 years; 49% were female and 53% Black. After 48 weeks, the estimated mean change in weight was -0.47% (95% CI: -2.09, 1.14) for the DOR + TAF/FTC arm, -2.73% (-4.22, -1.23) for DOR + TDF/FTC, and -1.84% (-3.37, -0.30) for INSTI + TAF/FTC. The estimated mean difference in weight change at 48 weeks for DOR versus INSTI (both with TAF/FTC) was 1.36 percentage points (97.5% CI: -1.20, 3.92) and -0.89 percentage points (-3.34, 1.57) for DOR + TDF/FTC versus INSTI + TAF/FTC. There was no evidence of variation by sex or race, nor of treatment differences for changes in fasting lipids, insulin resistance, fat mass, or bone mineral density. CONCLUSIONS: In people with HIV and obesity, switching from an INSTI + TAF/FTC regimen to DOR/FTC with either TAF or TDF did not produce clinically meaningful differences in weight change or metabolic health after 48 weeks.
引用
- Koethe JR, Lake JE, Kantor A, et al. A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). Clin Infect Dis. 2026. PMID: 41847923. doi:10.1093/cid/ciag196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。